PaxMedica, Inc. Stock

Equities

PXMD

US70424C2035

Biotechnology & Medical Research

Delayed OTC Markets 10:24:12 2024-06-10 am EDT 5-day change 1st Jan Change
0.2996 USD -3.98% Intraday chart for PaxMedica, Inc. -11.88% -60.42%
Sales 2024 * - Sales 2025 * - Capitalization 2.43M
Net income 2024 * -12M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.29 x
P/E ratio 2025 *
-
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.98%
1 week-11.88%
Current month-9.27%
1 month+44.73%
3 months-58.90%
6 months-58.12%
Current year-60.42%
More quotes
1 week
0.28
Extreme 0.28
0.39
1 month
0.21
Extreme 0.2051
0.39
Current year
0.20
Extreme 0.201
1.19
1 year
0.20
Extreme 0.201
24.31
3 years
0.20
Extreme 0.201
178.16
5 years
0.20
Extreme 0.201
178.16
10 years
0.20
Extreme 0.201
178.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 20-03-03
Director of Finance/CFO 44 22-06-30
Chief Tech/Sci/R&D Officer 67 23-08-15
Members of the board TitleAgeSince
Director/Board Member 78 22-09-30
Chief Executive Officer 64 20-03-03
Director/Board Member 40 19-02-28
More insiders
Date Price Change Volume
24-06-10 0.2996 -3.98% 2 818
24-06-07 0.312 -2.80% 25,121
24-06-06 0.321 0.00% 7,695
24-06-05 0.321 -2.73% 49,140
24-06-04 0.33 -2.94% 67,528

Delayed Quote OTC Markets, June 10, 2024 at 10:24 am EDT

More quotes
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.312 USD
Average target price
3 USD
Spread / Average Target
+861.54%
Consensus